A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles:
Related suggestion:
World Bank to further support health, nutrition in Laos16 black bear cubs rescued in Lao capitalHow a lollipop can help to spot the early signs of mouth cancerAngela Rayner fan Andy Burnham to have no role in police investigation into her housing affairsThe proof going vegan ISN'T better for you? Study finds plantTJ Maxx job applicant really wants to to work at the storeThe glare of car headlights could be a risk for heart conditions... As everHayao Miyazaki's animated fantasy stays atop Chinese box officeHayao Miyazaki's animated fantasy stays atop Chinese box officeRescuers battling forest fire in China's Sichuan
2.95s , 6501.8984375 kb
Copyright © 2024 Powered by Colon cancer blood test offers new screening option ,Global Gazetteer news portal